Weber L W, Bowne W B, Wolchok J D, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis J J, Houghton A N
The Swim Across America Laboratory, Sloan-Kettering Division, Cornell University Graduate School of Medical Sciences, New York 10021, USA.
J Clin Invest. 1998 Sep 15;102(6):1258-64. doi: 10.1172/JCI4004.
The immune system can recognize self antigens expressed by cancer cells. Differentiation antigens are prototypes of these self antigens, being expressed by cancer cells and their normal cell counterparts. The tyrosinase family proteins are well characterized differentiation antigens recognized by antibodies and T cells of patients with melanoma. However, immune tolerance may prevent immunity directed against these antigens. Immunity to the brown locus protein, gp75/ tyrosinase-related protein-1, was investigated in a syngeneic mouse model. C57BL/6 mice, which are tolerant to gp75, generated autoantibodies against gp75 after immunization with DNA encoding human gp75 but not syngeneic mouse gp75. Priming with human gp75 DNA broke tolerance to mouse gp75. Immunity against mouse gp75 provided significant tumor protection. Manifestations of autoimmunity were observed, characterized by coat depigmentation. Rejection of tumor challenge required CD4(+) and NK1.1(+) cells and Fc receptor gamma-chain, but depigmentation did not require these components. Thus, immunization with homologous DNA broke tolerance against mouse gp75, possibly by providing help from CD4(+) T cells. Mechanisms required for tumor protection were not necessary for autoimmunity, demonstrating that tumor immunity can be uncoupled from autoimmune manifestations.
免疫系统能够识别癌细胞所表达的自身抗原。分化抗原就是这些自身抗原的典型代表,由癌细胞及其正常细胞对应物表达。酪氨酸酶家族蛋白是黑色素瘤患者抗体和T细胞所识别的特征明确的分化抗原。然而,免疫耐受可能会阻止针对这些抗原的免疫反应。在同基因小鼠模型中研究了对棕色基因座蛋白gp75/酪氨酸酶相关蛋白-1的免疫反应。对gp75耐受的C57BL/6小鼠在用编码人gp75而非同基因小鼠gp75的DNA免疫后,产生了针对gp75的自身抗体。用人gp75 DNA进行预激发打破了对小鼠gp75的耐受。对小鼠gp75的免疫提供了显著的肿瘤保护作用。观察到了自身免疫的表现,其特征为被毛色素脱失。肿瘤攻击的排斥反应需要CD4(+)和NK1.1(+)细胞以及Fc受体γ链,但色素脱失不需要这些成分。因此,用同源DNA免疫可能通过CD4(+) T细胞提供帮助打破了对小鼠gp75的耐受。肿瘤保护所需的机制对于自身免疫并非必需,这表明肿瘤免疫可以与自身免疫表现相分离。